CYP2D6 genotype may moderate measures of brain structure in methamphetamine users

Area of Science:

• Neuroscience
• Pharmacogenetics
• Neuroimaging

Background:

• Chronic methamphetamine use is associated with neurotoxic effects and brain structure abnormalities.
• Cytochrome P450 2D6 (CYP2D6) plays a key role in methamphetamine metabolism, suggesting genetic variations may influence its neurotoxic impact.
• Individual differences in CYP2D6 activity could moderate the effects of methamphetamine on brain structure and cognitive function.

Purpose of the Study:

• To investigate the relationship between CYP2D6 genotype activity and brain structure and cognitive function in methamphetamine users.
• To determine if CYP2D6 genetic variations modify the neurotoxic effects of chronic methamphetamine use.

Main Methods:

• Genotyping for CYP2D6 variants to calculate an activity score.
• Assessing cognitive function (attention, memory, executive function) in 82 methamphetamine users and 79 controls.
• Utilizing structural magnetic resonance imaging (MRI) to measure whole brain cortical thickness and hippocampal volume in a subset of participants.

Main Results:

• A significant interaction between CYP2D6 activity score and group was found for cortical thickness (p = 0.024).
• Higher CYP2D6 activity was associated with thinner cortical thickness in methamphetamine users (p = 0.035), but not in controls.
• Trends for reduced hippocampal volume were observed in methamphetamine users with higher CYP2D6 activity, though not statistically significant.

Conclusions:

• CYP2D6 genotypes associated with higher enzyme activity may increase vulnerability to methamphetamine-induced brain structure deficits.
• The observed structural changes in methamphetamine users related to CYP2D6 activity warrant further investigation into their behavioral consequences.
• This study highlights the role of pharmacogenetics in understanding individual susceptibility to drug-induced neurotoxicity.